CJC-1295 binds the GHRH receptor. Ipamorelin binds a completely separate target, the ghrelin receptor. Both pathways converge on the same somatotroph cells releasing GH — which is the entire research rationale for combining them: additive stimulation through two parallel routes, not duplicated effort.
Research on this stack centers on GH pulse patterns and nitrogen metabolism — the biological basis for lean-mass preservation. A frequently cited study measured hepatic urea nitrogen synthesis under induced catabolic stress, using it as a proxy for how well the body holds onto protein during metabolic stress. The mechanism connecting that to lean mass is straightforward: better nitrogen balance, less breakdown.
The lean-mass case for this stack draws on the much larger body of research linking elevated GH circulation to muscle preservation and fat metabolism generally — including studies in older adults showing measurable strength gains following GH therapy. This is the foundation researchers build on when studying CJC-1295 + Ipamorelin specifically.
Direct trials isolating this exact combination’s effect on body composition are still limited — most of the supporting case is inferred from the broader GH-axis literature, which is a reasonable starting point for a research question, not a substitute for compound-specific data.
No. CJC-1295 targets the GHRH receptor. Ipamorelin targets the ghrelin receptor. That’s why researchers combine them — two separate pathways converging on GH release.
GH pulse amplitude, nitrogen retention, and downstream lean-mass and recovery signaling — with strong support from the broader growth-hormone literature.
Duration. This version produces a short, pulsatile GH release. DAC extends that window to days — sustained instead of pulsatile.
Sources Reviewed
1. Nass R, et al. Effects of an oral ghrelin mimetic on body composition in healthy older adults: a randomized trial. Ann Intern Med. 2008.
2. Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008.
View CJC-1295 + Ipamorelin 5mg -> bravalongevity.com/product/cjc-1295-ipamorelin-5mg/
This content is a literature review for research and educational purposes only. Brava Longevity products are sold strictly for research use only (RUO) and are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease. Statements have not been evaluated by the FDA.
